Dr Reddy’s launches Daptomycin antibiotic in US

Pharmaceutical firm Dr Reddy’s Laboratories Ltd said it has launched Daptomycin antibiotic in the US market.

Daptomycin is used alone or in combination with other medications to treat certain blood infections or serious skin infections caused by bacteria. It belongs to a class of medications called cyclic lipopeptide antibiotics.

Daptomycin is marketed in the United States under the brand name Cubicin by Cubist Pharmaceuticals.

Cubicin is a trademark drug of American pharma giant Merck Sharp and Dohme (MSD).

Cubicin and it generic versions had sales of $640 million in the US market for the past twelve months that ended in March 2019.

Daptomycin is available in single-dose 15 ml vials, said Dr Reddy’s.

Headquartered in Hyderabad, Dr Reddy’s manufactures and markets a wide range of pharmaceuticals in India and overseas.

The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products.